TCR2 and Bristol-Myers Squibb form a partnership to evaluate mesothelin-positive solid tumor cell therapy

TCR2 Therapeutics recently announced that it has reached a clinical trial cooperation agreement with Bristol-Myers Squibb (BMS) and plans to launch a phase 2 clinical trial to evaluate a new cell therapy gavocabtagene autoleucel (gavo-cel, TC-210) combined with anti-PD-1 therapy Opdivo (generic name: nivolumab, nivolumab) and anti-CTLA-4 therapy Yervoy (generic name: ipilimumab, ipilimumab), used for the treatment of refractory and mesothelial expression Solid tumors of mesothelin

The main purpose of this phase 2 trial is to evaluate the efficacy of gavo-cel in patients with unresectable, metastatic or recurrent mesothelin-expressing solid tumors, including non-small cell lung cancer (NSCLC), ovarian cancer, and malignant pleura/peritoneum Mesothelioma (MPM) and cholangiocarcinoma

The planned phase 2 clinical trial will evaluate the anti-tumor activity and better describe the safety of gavo-cel at the selected recommended phase 2 dose (RP2D)

Among them, patients with NSCLC, ovarian cancer, and cholangiocarcinoma will receive the combined treatment of gavo-cel and Opdivo

gavo-cel structure characteristics

gavo-cel is a new type of TRuC (T cell receptor fusion construct) cell therapy, which consists of autologous genetically engineered T cells expressing a single domain antibody and CD3ε subunit fusion protein.

Gavo-cel Phase 1 clinical trial data

gavo-cel was developed for the treatment of mesothelin-positive solid tumors

The phase 1/2 clinical trial of gavo-cel focuses on 4 indications: NSCLC, ovarian cancer, malignant pleural/peritoneal mesothelioma (MPM), and cholangiocarcinoma

In the interim data of the dose escalation part of the phase 1/2 clinical trial, it has been confirmed that gavo-cel has consistent clinical benefits.

Note: The original text has been deleted

Original source: TCR2 Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid Tumors